Literature DB >> 21736688

The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern.

C J Currie1, J A Johnson.   

Abstract

There is no doubt about the value of exogenous insulin for people with type 1 diabetes. The purpose of this commentary is to discuss emerging evidence that this may not be the case for the majority of people with type 2 diabetes.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21736688     DOI： 10.1111/j.1463-1326.2011.01469.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN： 1462-8902            Impact factor:   6.577


  16 in total

1.  ADVANCE and glycaemia thresholds: a need to clarify the statistical approach.

Authors:  C J Currie
Journal:  Diabetologia       Date:  2012-05-18       Impact factor: 10.122

Review 2.  Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.

Authors:  Avivit Cahn; Simona Cernea; Itamar Raz
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

3.  The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.

Authors:  Stanley S Schwartz; Solomon Epstein; Barbara E Corkey; Struan F A Grant; James R Gavin; Richard B Aguilar
Journal:  Diabetes Care       Date:  2016-02       Impact factor: 19.112

4.  Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 Diabetes.

Authors:  Peter C Butler
Journal:  JAMA Intern Med       Date:  2016-10-01       Impact factor: 21.873

5.  Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin.

Authors:  Sarah E Holden; Chris D Poole; Christopher Ll Morgan; Craig J Currie
Journal:  BMJ Open       Date:  2011-01-01       Impact factor: 2.692

6.  Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Authors:  Carlos Vallarino; Alfonso Perez; Gregory Fusco; Huifang Liang; Morgan Bron; Sudhakar Manne; Guiandre Joseph; Shawn Yu
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

7.  Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.

Authors:  Craig J Currie; Chris D Poole; Marc Evans; John R Peters; Christopher Ll Morgan
Journal:  J Clin Endocrinol Metab       Date:  2013-01-31       Impact factor: 5.958

Review 8.  Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review.

Authors:  Hilary I Price; Meghan D Agnew; John-Michael Gamble
Journal:  BMJ Open       Date:  2015-03-11       Impact factor: 2.692

Review 9.  Role of insulin in the type 2 diabetes therapy: past, present and future.

Authors:  Carlo Maria Rotella; Laura Pala; Edoardo Mannucci
Journal:  Int J Endocrinol Metab       Date:  2013-07-01

10.  Exposure to excess insulin (glargine) induces type 2 diabetes mellitus in mice fed on a chow diet.

Authors:  Xuefeng Yang; Shuang Mei; Haihua Gu; Huailan Guo; Longying Zha; Junwei Cai; Xuefeng Li; Zhenqi Liu; Wenhong Cao
Journal:  J Endocrinol       Date:  2014-04-16       Impact factor: 4.286
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.